Investors will remember that 2019 wasn’t a great year for cannabis stocks, especially Canadian stocks. Issues from uncertainty over Canada’s national elections to shortage of cannabis retail stores in Ontario greatly weighed on Canadian cannabis stocks last year. These problems are largely out of the way and investors can now spot cannabis stocks with a promising outlook in 2020. Tetra Bio-Pharma (CVE:TBP) (OTCMKTS:TBPMF) is one play poised for a big breakout in 2020 as its drug products go on sale.
Tetra Bio-Pharma is one of the most promising cannabis stocks in 2020 and investors have really warmed up to the stock. At $0.50, Tetra stock has already gained more than 60% year-to-date. But that is just the beginning and we feel there is a great story to tell here. First, however, it is important for investors to understand the company we’re discussing.
About Tetra Bio-Pharma
For investors who may have just come across Tetra Bio-Pharma for the very first time, this is a Canadian cannabis company. It is focused on developing cannabis-based drugs for a variety of conditions, including cancer.
Tetra Bio-Pharma about to begin commercializing its drug products
As a drug company, Tetra Bio-Pharma is insulated from many challenges that face conventional cannabis companies. For example, companies that make adult-use cannabis products must cope with cutthroat competition in the market. Moreover, Canadian cannabis companies have struggled with a shortage of cannabis retail stores, especially in the key Ontario market. At the end of 2019, there were only about 25 cannabis shops open in Ontario, which is enough to serve a province of more than 14 million consumers. However, the Ontario administration recently stepped in to address this problem and more stores are expected to open in 2020. Still, makers of adult-use cannabis products in Canada have to contend with a thriving black market. Tetra doesn’t face these problems.
But the most exciting thing about Tetra in 2020 is its drug products going on sale this year. This is an important development that will keep drawing more investors to the stock as they realize how Tetra’s outlook is about to change dramatically.
Tetra Bio-Pharma secures Health Canada approval to bring its TERPACAN drug products to market
Tetra Bio-Pharma recently received Health Canada approval to begin commercialization of its two Terpacan drug products in the country. One of the Terpacan products is meant for the treatment of hemorrhoids and the other is meant for back and muscle pain.
Tetra intends to bring the Terpacan products to market as soon as possible. Toward that end, the company announced on January 20 it has selected a manufacturing partner that will produce the drugs. Moreover, Tetra has selected a sales partner that will market and distribute its Terpacan drugs in Canada. Tetra emphasized that it picked a sales partner with a good track record. Tetra targets its Terpacan products to hit drugstores by June 2020.
While the Terpacan drugs will initially go on sale in Canada, Tetra has set its sights on the US market as well. It is currently awaiting final approval from the US Food and Drug Administration to begin commercialization of Terpacan products in the US.
Tetra signs Azevedos to sell its pain drug Caumz in Portugal
In addition to Terpacan, Tetra’s other drug product is Caumz, which is designed for the treatment of pain and inflammation. In December, Tetra signed respected Portuguese pharmaceutical brand Azevedos Indústria Farmacêutica to market and distribute Caumz in Portugal. Under that arrangement, Tetra will receive milestone payments and share profits from the sale of Caumz.
The chronic pain treatment market that Tetra is targeting with Caumz was worth $69.3 billion in 2017 and is on track to hit $105.9 billion by 2024.
Tetra forms joint venture to enter Irritable Bowel Syndrome treatment market
In August last year, Tetra teams up with Thorne Research and Onegevity Health to form a joint venture business called CB2 Therapeutics. Among other things, CB2 Therapeutics will focus on developing treatments for irritable bowel syndrome. The global irritable bowel syndrome treatment market was valued at $2.6 billion in 2018 and is on course to grow to $8.7 billion by 2025.
Investors still have memories of the broad collapse of cannabis stocks last year. That is why in 2020 investors are carefully screening pot stocks for the best of the breed. In light of what we’ve just seen above, Tetra Bio-Pharma is no doubt a strong candidate.
We will be updating our subscribers as soon as we know more. For the latest updates on Tetra Bio-Pharma, sign up below!
Disclosure: We have no position in Tetra Bio-Pharma and have not been compensated for this article.
What Do Investors See In Medical Marijuana Stock (OTCMKTS:MJNA)?
Medical Marijuana Stock (OTCMKTS:MJNA) has emerged as one of many investor’s favorite pot stocks in the legal cannabis universe in 2020. The stock is already up about 10% in 2020, demonstrating how investors have warmed up to the stock early on in the New Year.
Following a disastrous 2019, cannabis investors lost money but have also learned that their best bets are stocks with strong fundamentals. They are looking for companies that have positioned themselves well in the cannabis industry and have what it takes to go for the opportunities. That is why MJNA stock is catching a lot of investor attention in 2020 because of how it has positioned itself in the cannabis market.
Robust revenue growth and strong financial position have also helped put MJNA on the radar of investors hunting for quality cannabis stocks. Revenue at MJNA more than doubled from $26.5 million in 2017 to $60 million in 2018. MJNA is also not in financial distress as may be the case with other cannabis companies out there. The company finished the third quarter, the most recent reported period, with $5.5 million in cash reserves.
Moreover, MJNA has recently taken steps to expand into new international markets and invest in companies that are leaders in their segments. These prudent actions are helping lift Medical Marijuana stock as more investors learn about them.
About Medical Marijuana stock
Is Tilray Inc (NASDAQ:TLRY) A Buy Or Sell?
For Tilray Inc (NASDAQ:TLRY) and the rest of cannabis stocks, 2019 was no doubt a bad year. But 2020 is shaping up to be a promising year for the stock. To start with, Tilray stock has already gained 8.35% year-to-date. If that says anything, it shows following the broad selloff in Tilray stock last year, we’ve got to a point where sellers are giving way to buyers in the stock.
There are several catalysts that should continue driving NASDAQ:TLRY as you’re about to see. First, below is a brief profile of the company we’re discussing.
Tilray is a Canada-headquartered global cannabis company. It is engaged in activities of cannabis cultivation and processing as well as marketing and distribution of cannabis products. Tilray already has several cannabis products brands to its portfolio. It operates across five continents through subsidiaries in Canada, Australia, Germany, and Portugal.
Following the broad collapse of cannabis stocks in 2019, investors are looking for cannabis stocks that can make a positive impact on their portfolios in 2020. Tilray stands out as an attractive cannabis stock pick in 2020. Here are some of the exciting things about the company.
Tilray CEO sees a bright future for the cannabis industry
On January 25, Tilray CEO Brendan Kennedy spoke on Bloomberg. In that interview, Kennedy framed a rosy outlook for the…
Is Cronos Stock (TSE:CRON)(NASDAQ:CRON) A Buy?
Cronos Stock (TSE:CRON)(NASDAQ:CRON) stock fell 9.22% on January 24, marking its steepest decline so far in 2020. The stock plunge followed an important disclosure that you would only expect from a company that is trying to be straight and transparent with investors. Here’s what happened.
On January 22, after market close, Cronos made a regulatory filing detailing changes in its executive team. In that SEC filing, Cronos revealed that David Hsu and William Hilson have stepped down as its chief operating officer and chief commercial officer, respectively. Unfortunately, some investors read bad news in the executive exits and sold their shares in Cronos.
But a careful reading of the filing doesn’t seem to raise any red flags. Therefore, the big stock plunged points to investors panicking to the degree of responding to a mosquito bite with a missile.
There is no doubt that 2019 was a difficult year for cannabis stocks and Cronos Stock is no exception. But before the uncalled for reaction to Cronos’s regulatory filing, we had been at a point where sellers were starting to give way to buyers in Cronos stock. The stock has gained about 8.0% in the past one month. It had gained more than 13% year-to-date before the January 24 big selloff.
About Cronos Stock
Cronos Stock is a Canada-based global cannabis company. Cronos operates through subsidiaries and…